Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population

Carcinogenesis

Volumn 31, Issue 6, 2010, Pages 1080-1086

  Dong, Jing ^a   Dai, Juncheng ^a   Shu, Yongqian ^a,b   Pan, Shiyang ^c   Xu, Lin ^d   Chen, Wenping ^e   Wang, Yi ^e   Jin, Guangfu ^a   Ma, Hongxia ^a   Zhang, Mingfeng ^a   Hu, Zhibin ^a   Shen, Hongbing ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Key Laboratory of Chinese Medicine Processing   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d JIANGSU CANCER HOSPITAL   (China)

^e Nanjing Brain Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANINE; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; CHINA; COHORT ANALYSIS; GENETICS; LUNG TUMOR; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953937410     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq079     Document Type: Article

References (48)

1. Parkin, D.M. et al. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
2. Yang, L. et al. (2005) Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol. Biomarkers Prev., 14, 243-250.
3. Yang, L. et al. (2004) Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br. J. Cancer, 90, 2157-2166.
4. Parkin, D.M. et al. (2005) Mortality time trends and the incidence and mortality estimation and projection for lung cancer in China. Chin. J. Lung Cancer, 4, 274-278.
5. Chen, H.Y. et al. (2007) A five-gene signature and clinical outcome in nonsmall-cell lung cancer. N. Engl. J. Med., 356, 11-20.
6. Shibata, T. et al. (2005) Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin. Cancer Res., 11, 6177-6185.
7. Tabernero, J. (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res., 5, 203-220.
8. Herbst, R.S. et al. (2005) Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol., 23, 2544-2555.
9. Herbst, R.S. et al. (2004) Gefitinib-a novel targeted approach to treating cancer. Nat. Rev. Cancer, 4, 956-965.
10. Yarden, Y. et al. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol., 2, 127-137.
11. Weiss, W.A. et al. (2003) Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res., 63, 1589-1595.
12. Brandt, R. et al. (2000) Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene, 19, 2129-2137.
13. Selvaggi, G. et al. (2004) Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann. Oncol., 15, 28-32.
14. Ohsaki, Y. et al. (2000) Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol. Rep., 7, 603-607.
15. Carmeliet, P. et al. (2000) Angiogenesis in cancer and other diseases. Nature, 407, 249-257.
16. Nilsson, M. et al. (2006) Vascular endothelial growth factor (VEGF) pathway. J. Thorac. Oncol., 1, 768-770.
17. Ferrara, N. (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol., 29, 10-14.
18. Fontanini, G. et al. (1997) Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J. Natl Cancer Inst., 89, 881-886.
19. Yuan, A. et al. (2001) Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J. Clin. Oncol., 19, 432-441.
20. Giatromanolaki, A. et al. (2000) 'Invading edge vs. inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J. Pathol., 192, 140-149.
21. Ellis, L.M. (2004) Epidermal growth factor receptor in tumor angiogenesis. Hematol. Oncol. Clin. North Am., 18, 1007-1021, viii.
22. Perrotte, P. et al. (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 5, 257-265.
23. Pore, N. et al. (2006) EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res., 66, 3197-3204.
24. Hirata, A. et al. (2002) ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res., 62, 2554-2560.
25. Ciardiello, F. et al. (2003) Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res., 9, 1546-1556.
26. Jin, G. et al. (2009) Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population. Int. J. Cancer, 124, 2172-2178.
27. Hu, Z. et al. (2008) Genetic variants of miRNA sequences and non-small cell lung cancer survival. J. Clin. Invest., 118, 2600-2608.
28. Hu, Z. et al. (2007) Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis. Hum. Mutat., 28, 431-440.
29. Araujo, A. et al. (2007) Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist, 12, 201-210.
30. Barker, F.G. II et al. (2001) EGFR overexpression and radiation response in glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys., 51, 410-418.
31. Sheridan, M.T. et al. (1997) Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat. Oncol. Investig., 5, 180-186.
32. Zhou, Q. et al. (2006) EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues. Cancer Biol. Ther., 5, 1445-1449.
33. Kang, D. et al. (2005) Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factoralpha (TGFA) gene and risk of oral cancer in Puerto Rico. Pharmacogenet. Genomics, 15, 343-347.
34. Kimura, T. et al. (2006) Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. Oncol. Rep., 15, 1205-1210.
35. Liu, W. et al. (2005) A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res., 65, 46-53.
36. McInerney, J.M. et al. (2001) A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells. J. Cell. Biochem., 80, 538-549.
37. Amador, M.L. et al. (2004) An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res., 64, 9139-9143.
38. Laskin, J.J. et al. (2004) Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat. Rev., 30, 1-17.
39. Folkman, J. et al. (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, 339, 58-61.
40. Ellis, L.M. et al. (1996) Angiogenesis and metastasis. Eur. J. Cancer, 32A, 2451-2460.
41. Takahashi, Y. et al. (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res., 55, 3964-3968.
42. Ferrara, N. et al. (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med., 5, 1359-1364.
43. Lu, H. et al. (2005) Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res., 65, 5015-5019.
44. Tzanakis, N. et al. (2006) Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J. Surg. Oncol., 94, 624-630.
45. Heist, R.S. et al. (2008) VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J. Clin. Oncol., 26, 856-862.
46. Hefler, L.A. et al. (2007) Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin. Cancer Res., 13, 898-901.
47. Masago, K. et al. (2009) Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci., 100, 1917-1922.
48. Wacholder,S. et al. (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl Cancer Inst., 96, 434-442.